

Disclosures

Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Ancora	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Cytokinetics	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
NIH	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
HFSA	Other - Guest Editor - JCF	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
HFSA	Other - ASM Committee	None (\$0)	Heart Failure and Cardiomyopathies

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
DepleTTR	Alexion	
CORCINCH-HF	Ancora Heart, Inc	Ancora Heart, Inc
TAVR Unload	Cardiovascular Research Foundation (CRF)	
Donor-Derived Cell-free DNA – Outcomes AlloMap Registry	CareDx, Inc.	
Eli Lilly Protocol J2L-MC-EZBB	Eli Lilly & Company	
PROACTIV-HF-2	Endotronix	
APOLLO Trial	Medtronic	
VICTOR	Merck & Co., Inc.	
ATHENA	NOVO-NORDISK	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2023	LVAD candidate selection	Plaintiff	LVAD complication	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/5/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/5/2025

Embargo | Signed on 8/5/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 8/5/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.